As 2024 comes to an end, Neola Medical highlights a year of significant advancements including the company’s transition from technical verification phase to clinical validation phase, preparing for clinical studies on preterm born babies.
“In 2024, we reached two significant milestones that are essential for our upcoming FDA application: securing the CB certificate and successfully completing the Human Factors Validation study with nurses in the U.S. These accomplishments mark our transition from the technical verification to the clinical validation phase, preparing for our first clinical study on preterm born babies with our continuous lung monitoring device, Neola®.”, says CEO Hanna Sjöström.
Read more about the latest news in the investor letter winter 2024, attached to this press release and available on the company’s website www.neolamedical.com